GHRP-6 vs Sermorelin.

GHRP-6 (growth hormone-releasing peptide-6) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. First described by endocrinologist Cyril Y. Bowers and colleagues in the mid-1980s, it was the prototype of the growth hormone secretagogue (GHS) class and the chemical ancestor of later peptides such as GHRP-2, hexarelin, and ipamorelin. It is not a hormone replacement; rather, it provokes the body's own pituitary to release growth hormone.

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal 1-29 fragment of human growth hormone-releasing hormone (GHRH), the hypothalamic hormone that signals the pituitary to release growth hormone (GH). This 1-29 fragment is the shortest portion of GHRH that retains full biological activity, so sermorelin behaves as a functional GHRH analog (a "secretagogue") rather than as growth hormone itself. It was marketed under the brand names Geref and Geref Diagnostic.

GHRP-6 is a synthetic agonist of the growth hormone secretagogue receptor 1a (GHS-R1a), the G-protein-coupled receptor cloned in 1996 whose endogenous ligand, ghrelin, was identified in 1999. Receptor activation drives phospholipase C signaling, raising inositol trisphosphate and diacylglycerol, mobilizing intracellular calcium and activating protein kinase C, which triggers GH release from somatotrophs. This pathway is distinct from and synergistic with GHRH (which signals through cAMP/PKA), and GHRP-6 also acts on the hypothalamus to amplify GHRH tone and suppress somatostatin. Separately, GHRP-6 binds the scavenger receptor CD36, which is implicated in its proposed cytoprotective and anti-ischemic effects independent of GH release. It also stimulates appetite (via NPY/AgRP arcuate neurons) and can transiently raise cortisol and prolactin.

Sermorelin binds the GHRH receptor on pituitary somatotroph cells, a Gs-protein-coupled receptor, raising intracellular cAMP and stimulating synthesis and pulsatile secretion of endogenous growth hormone. Because it acts upstream on the pituitary rather than supplying exogenous GH, its effect is gated by an intact pituitary and remains subject to normal physiological brakes, most importantly negative feedback from somatostatin and from GH/IGF-1. Downstream, any GH released drives hepatic production of insulin-like growth factor 1 (IGF-1). This "releaser" mechanism is the basis for the long-standing claim that sermorelin produces a more physiologic, pulsatile GH profile than direct recombinant GH injection, though that pharmacodynamic difference has not been shown to translate into superior clinical outcomes.

In humans, the best-established data are pharmacological/diagnostic: GHRP-6 reliably and synergistically stimulates GH secretion (especially combined with GHRH) and was studied as a GH-provocative agent and probe of the somatotropic axis in the 1990s. Beyond GH provocation, the much-publicized cytoprotective, cardioprotective, and wound/scar-reducing claims rest almost entirely on preclinical work: rodent myocardial infarction and reperfusion models, a rat/rabbit wound and hypertrophic-scar study (Plastic Surgery International, 2016, animal-only), and doxorubicin-cardiotoxicity models. A Clinical Science (2006) paper proposed GHRP-6 for prevention of multiple organ failure, but this remained largely conceptual/preclinical. There are no large, completed, peer-reviewed randomized human trials demonstrating clinical benefit for cardioprotection, healing, or body composition; the human-versus-animal gap here is wide and should not be glossed over.

The strongest human evidence is in pediatric diagnostics and idiopathic GH deficiency: sermorelin was studied and FDA-approved both as a provocative test of pituitary GH reserve and for treating growth failure in children with GHRH-responsive (hypothalamic) GH deficiency, where it can increase growth velocity (reviewed in BioDrugs 1999, PMID 18031173). Evidence for the popular adult "anti-aging," body-composition, sleep, and recovery claims is largely mechanistic or extrapolated rather than demonstrated; a frequently cited Clinical Interventions in Aging review (PMID 18046908) frames sermorelin in adult GH insufficiency as a rational but largely hypothetical approach, not an outcome-proven therapy. Notably, the well-known randomized controlled trial showing cognitive benefit from a GHRH analog in older adults and mild cognitive impairment (Baker et al., Archives of Neurology 2012, PMID 22869065) used tesamorelin, a different stabilized GHRH(1-44) analog, not sermorelin, so it should not be cited as direct sermorelin evidence. Overall, robust randomized trials of sermorelin for adult quality-of-life, longevity, or athletic outcomes are essentially absent.

Documented effects in human GH-testing studies include marked stimulation of appetite and transient, usually modest, increases in cortisol and prolactin alongside the intended GH rise, reflecting limited receptor selectivity compared with newer agents like ipamorelin. Because GHS-R1a agonism raises GH and downstream IGF-1, theoretical concerns include fluid retention, insulin resistance/altered glucose handling, and the general caution that sustained GH/IGF-1 elevation could promote growth of existing tumors; these long-term risks are not well characterized for GHRP-6 specifically. There are no robust long-term human safety data, no established safety in pregnancy, and product purity/identity is a major real-world hazard since material sold for "research" is unregulated. No dosing or administration guidance is provided here.

In its approved pediatric and diagnostic use, sermorelin was generally well tolerated, with the most common reactions being transient injection-site reactions (redness, swelling, pain) and, less often, flushing, headache, dizziness, or transient warmth; uncommon hypersensitivity reactions were reported. Because it raises GH and IGF-1, the theoretical class concerns that apply to GH-axis stimulation are relevant, including fluid retention, joint or muscle discomfort, insulin resistance/glucose changes, and the general caution around GH-axis stimulation in people with active malignancy. Most safety data come from short-term, monitored, mostly pediatric settings; long-term safety of chronic adult use, especially via compounded products sold for off-label "wellness" purposes, has not been established, and compounded preparations carry additional uncertainty around purity, sterility, and dose accuracy. No doses or regimens are provided here.

GHRP-6 is not approved by the FDA (or other major regulators) for any therapeutic indication and is an investigational/research-use-only compound. As a growth hormone secretagogue, it falls under substances prohibited in sport at all times by the World Anti-Doping Agency (WADA).

Sermorelin acetate was FDA-approved (brand Geref / Geref Diagnostic) for diagnostic testing of pituitary GH reserve and for idiopathic GH deficiency in children, but the branded products were voluntarily withdrawn from the US market in 2008 for commercial reasons (not for safety or efficacy failures); it is currently available in the US only as a compounded preparation, with no FDA-approved finished-drug product on the market.